+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Meningococcal Vaccines Market by Vaccine Type, Serogroup Coverage, Distribution Channel, End User, Age Group, Formulation, Indication - Global Forecast to 2030- Product Image
Meningococcal Vaccines Market by Vaccine Type, Serogroup Coverage, Distribution Channel, End User, Age Group, Formulation, Indication - Global Forecast to 2030- Product Image
Sale

Meningococcal Vaccines Market by Vaccine Type, Serogroup Coverage, Distribution Channel, End User, Age Group, Formulation, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4857895
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Meningococcal Vaccines Market grew from USD 5.95 billion in 2024 to USD 6.60 billion in 2025. It is expected to continue growing at a CAGR of 10.75%, reaching USD 10.98 billion by 2030.

Unveiling the Crucial Role of Meningococcal Vaccines

Meningococcal disease remains a formidable global health challenge, characterized by rapid onset and potentially severe outcomes. Vaccination programs have significantly reduced incidence rates across diverse populations, yet evolving serogroups and emerging risk factors continue to pressure public health infrastructures. Conjugate, polysaccharide, and protein subunit vaccines have each demonstrated unique strengths, driving innovation in formulation and delivery to enhance immunogenicity and long-term protection.

This executive summary synthesizes essential insights into the current landscape of meningococcal vaccines, offering decision-makers a cohesive overview of transformative trends, tariff implications, segmentation nuances, and regional drivers. By integrating primary interviews, robust secondary research, and expert validation, this report equips stakeholders with a clear framework to navigate market complexities, optimize strategic initiatives, and anticipate future disruptions.

Evolving Drivers Reshaping the Global Vaccination Landscape

The meningococcal vaccines landscape is undergoing a paradigm shift fueled by advances in antigen design and regulatory harmonization. Next-generation protein subunit platforms are enhancing safety profiles while expanding serogroup coverage, and quadrivalent formulations are setting new benchmarks for broad-spectrum protection against A, C, W, and Y strains. Digital health integration and real-time surveillance systems are streamlining outbreak response, enabling rapid deployment in both endemic and travel-related contexts.

Policy realignments in emerging economies, coupled with heightened focus on adolescent and geriatric immunization, are compelling manufacturers to diversify portfolio offerings. Partnerships between biopharma innovators and public health agencies are accelerating routine prophylactic initiatives, while differentiated distribution models are reshaping access by bridging hospital pharmacies, online channels, and public health clinics. Collectively, these shifts underscore a dynamic market poised for sustained growth and targeted impact.

Navigating the Impact of New US Tariffs on Vaccine Economics

The recently enacted US tariffs for 2025 introduce a complex layer of economic considerations for vaccine manufacturers and importers. Increases on raw materials, adjuvants, and packaging components are amplifying production costs, prompting strategic realignments in global supply chains. Producers are evaluating nearshoring options and seeking tariff mitigation through bilateral trade agreements to preserve competitive pricing while maintaining quality standards.

These developments are also influencing tender structures for public health procurement, as buyers reassess budget allocations to accommodate higher landed costs. Private sector providers are exploring cost-sharing mechanisms with philanthropic organizations to sustain outreach in vulnerable communities. By anticipating these fiscal pressures, industry participants can fortify resilience strategies, negotiate favorable terms with suppliers, and recalibrate promotional efforts to reflect revised cost structures.

Dissecting Market Segmentation to Reveal Strategic Avenues

Market segmentation reveals strategic windows of opportunity across multiple dimensions. Conjugate vaccines remain the backbone of immunization programs, yet polysaccharide formulations retain relevance in rapid outbreak response scenarios. Protein subunit candidates are advancing through late-stage trials, offering differentiated safety and immunogenicity benefits. Serogroup coverage analysis highlights growing demand for quadrivalent options, while monovalent Group B and C offerings continue to capture niche segments driven by regional epidemiology.

Distribution channel dynamics show hospital pharmacies commanding substantial volumes, complemented by rising online pharmacy adoption and expanded public health clinic networks. End users span clinical settings, research institutes driving innovation, and dedicated vaccination centers coordinating mass immunization efforts. Age group targeting extends from pediatric schedules through adolescent boosters to adult and geriatric revaccination strategies. Formulation insights underscore a shift toward single dose prefilled syringes for enhanced compliance, even as multi dose vials persist in cost-sensitive markets. Indication focus remains balanced between routine prophylactic campaigns, traveler immunization programs, and agile outbreak response deployments.

Regional Dynamics Driving Demand and Distribution Patterns

Regional insights illuminate diverse growth trajectories and access challenges. In the Americas, robust public funding mechanisms underpin high uptake of conjugate and quadrivalent vaccines, while private market channels drive premium single dose syringe adoption. Latin American initiatives are expanding routine adolescent immunization, supported by regional procurement alliances.

Across Europe, Middle East & Africa, regulatory harmonization is accelerating clinical approvals for novel protein subunit platforms, yet supply constraints persist in select African nations. Collaborative frameworks are enhancing distribution to rural clinics, and cross-border outbreak response protocols are strengthening preparedness for emerging serogroup outbreaks. In Asia-Pacific, expanding healthcare infrastructure is catalyzing market penetration in China, India, and Southeast Asia, with digital pharmacies and retail networks improving last-mile access. Government-led traveler immunization programs and tailored geriatric booster campaigns are further bolstering regional vaccine uptake.

Corporate Strategies Steering the Competitive Arena

Leading biopharmaceutical companies are intensifying R&D investments to maintain competitive advantage. Market incumbents leverage advanced conjugation technologies and adjuvant platforms to refine immunogenic profiles, while emerging players are forging strategic alliances to expedite late-stage vaccine candidates. Consolidation activities, including targeted acquisitions and joint ventures, are reshaping the competitive landscape to ensure robust pipeline diversification.

Simultaneously, manufacturers are optimizing global manufacturing footprints through capacity expansions in strategic locations and technology transfers to contract development and manufacturing organizations. Pricing strategies are evolving to include value-based agreements and tiered pricing models, enabling broader adoption across public and private sectors. These corporate maneuvers are defining market share trajectories and setting the stage for sustained innovation.

Actionable Pathways to Strengthen Market Position

Industry leaders should prioritize diversification of supply chains to mitigate tariff-induced cost volatility, exploring nearshore manufacturing and multi-source procurement. Investment in next-generation protein subunit platforms will differentiate product portfolios and address unmet safety and coverage needs. Stakeholders must also cultivate digital distribution partnerships to streamline access and enhance patient engagement across all end user segments.

Engagement with policymakers and health authorities is critical to shape conducive reimbursement frameworks and support routine prophylactic programs. Strategic outreach to adolescent and geriatric populations through tailored education campaigns will drive immunization adherence. Finally, establishing robust outbreak response protocols with public health entities will ensure rapid deployment capabilities, safeguarding market stability and reinforcing corporate social responsibility commitments.

Robust Methodological Framework Underpinning the Analysis

This analysis is underpinned by a rigorous methodological framework combining primary and secondary research. Expert interviews across manufacturers, healthcare providers, and regulatory agencies provided qualitative insights, while comprehensive review of public filings and scientific literature contributed quantitative validation. Segmentation mapping was performed to align diverse market dimensions, ensuring robust cross-validation between data sources.

Geographical and company profiles were constructed through meticulous data triangulation, integrating trade statistics, patent databases, and clinical trial registries. All findings underwent peer review by domain specialists to guarantee accuracy and relevance. This holistic approach ensures the findings reflect real-world market dynamics and deliver actionable intelligence.

Synthesizing Insights for Informed Decision Making

The global meningococcal vaccines market is characterized by rapid innovation, evolving regulatory landscapes, and shifting economic imperatives. Strategic segmentation analysis reveals targeted growth pockets across vaccine type, serogroup coverage, distribution channels, end users, age groups, formulation, and indication. Regional dynamics further underscore divergent adoption patterns and access challenges that demand nuanced engagement.

Competitive forces are intensifying as leading companies streamline portfolios, pursue M&A activities, and implement differentiated pricing strategies. Simultaneously, industry leaders must navigate tariff disruptions while fostering public-private partnerships and strengthening outbreak response capabilities. By synthesizing these insights, stakeholders can calibrate strategic priorities, optimize resource allocation, and position themselves for sustainable leadership in the evolving meningococcal vaccines landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Conjugate
    • Polysaccharide
    • Protein Subunit
  • Serogroup Coverage
    • Bivalent
    • Monovalent C
    • Monovalent Group B
    • Quadrivalent
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Public Health Clinics
    • Retail Pharmacy
  • End User
    • Clinics
    • Hospitals
    • Research Institutes
    • Vaccination Centers
  • Age Group
    • Adolescent
    • Adult
    • Geriatric
    • Pediatric
  • Formulation
    • Multi Dose
      • Vial
    • Single Dose
      • Pre Filled Syringe
      • Vial
  • Indication
    • Outbreak Response
    • Routine Prophylactic
    • Traveler Immunization
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Hualan Biological Engineering Inc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Meningococcal Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Conjugate
8.3. Polysaccharide
8.4. Protein Subunit
9. Meningococcal Vaccines Market, by Serogroup Coverage
9.1. Introduction
9.2. Bivalent
9.3. Monovalent C
9.4. Monovalent Group B
9.5. Quadrivalent
10. Meningococcal Vaccines Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Public Health Clinics
10.5. Retail Pharmacy
11. Meningococcal Vaccines Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
11.5. Vaccination Centers
12. Meningococcal Vaccines Market, by Age Group
12.1. Introduction
12.2. Adolescent
12.3. Adult
12.4. Geriatric
12.5. Pediatric
13. Meningococcal Vaccines Market, by Formulation
13.1. Introduction
13.2. Multi Dose
13.2.1. Vial
13.3. Single Dose
13.3.1. Pre Filled Syringe
13.3.2. Vial
14. Meningococcal Vaccines Market, by Indication
14.1. Introduction
14.2. Outbreak Response
14.3. Routine Prophylactic
14.4. Traveler Immunization
15. Americas Meningococcal Vaccines Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Meningococcal Vaccines Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Meningococcal Vaccines Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. GlaxoSmithKline plc
18.3.2. Pfizer Inc.
18.3.3. Sanofi S.A.
18.3.4. Merck & Co., Inc.
18.3.5. Hualan Biological Engineering Inc
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. MENINGOCOCCAL VACCINES MARKET MULTI-CURRENCY
FIGURE 2. MENINGOCOCCAL VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BIVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MONOVALENT C, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MONOVALENT GROUP B, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PUBLIC HEALTH CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY OUTBREAK RESPONSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ROUTINE PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRAVELER IMMUNIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 64. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 69. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 70. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 118. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 127. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 128. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 133. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 134. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 145. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 146. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 151. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 152. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 154. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 155. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 158. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 160. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 161. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 190. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 191. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 194. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 196. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 197. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 208. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 209. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 212. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 213. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 214. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 215. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 223. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 224. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 244. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 245. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 248. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 249. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 250. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 251. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 253. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 254. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 258. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 259. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 260. TURKEY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 271. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 275. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 276. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 277. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 278. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 280. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 281. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 286. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 287. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 307. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 308. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 309. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 312. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 314. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 315. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 316. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 317. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 318. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 322. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 323. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 324. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 325. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 326. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 327. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 330. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 331. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MULTI DOSE, 2018-2030 (USD MILLION)
TABLE 332. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY SINGLE DOSE, 2018-2030 (USD MILLION)
TABLE 333. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY SEROGROUP COVERAGE, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA MENINGOCOCCAL

Companies Mentioned

The companies profiled in this Meningococcal Vaccines market report include:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Hualan Biological Engineering Inc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.98 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2024-2032 - Product Image

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Meningococcal Vaccines Market Report 2025 - Product Image

Meningococcal Vaccines Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Meningococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Meningococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Meningococcal Vaccines Market Report and Forecast 2024-2032 - Product Image

Meningococcal Vaccines Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From

About the Meningococcal Vaccine Market

The Meningococcal Vaccine is a type of vaccine used to protect against meningococcal disease, a serious and potentially fatal infection caused by the bacterium Neisseria meningitidis. It is recommended for adolescents and young adults, as well as for those at increased risk of infection, such as travelers to certain countries and those with certain medical conditions. The vaccine is available in both conjugate and polysaccharide forms, and is typically administered in two or three doses. The Meningococcal Vaccine market is part of the larger Infectious Diseases Drugs market, which includes a range of treatments for various infectious diseases. The Meningococcal Vaccine market is expected to grow in the coming years, driven by increasing awareness of the disease and the availability of new vaccines. Some companies in the Meningococcal Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.